Skyrizi (risankizumab) is a biologic therapy that targets interleukin-23, a protein involved in inflammatory joint and skin conditions. At Scottsdale Rheumatology Center, our physicians evaluate and manage Skyrizi therapy, including IV induction infusions for eligible patients, in our in-house infusion suite.
Skyrizi is commonly prescribed for:
For certain indications, Skyrizi treatment begins with IV induction infusions, administered by our specially trained infusion nurses, before transitioning to maintenance dosing. Our physicians determine the appropriate treatment path based on your diagnosis and monitor your response over time.
Before starting Skyrizi, our physicians review your medical history, including screening for infections such as tuberculosis. Ongoing monitoring helps our team track your response and address any concerns. Discuss the full risks and benefits of Skyrizi with your physician.
Our office can help coordinate prior authorization for Skyrizi therapy with most major insurance plans. Visit our Health Insurance page for more information.
For certain conditions, Skyrizi treatment begins with IV induction infusions before transitioning to at-home maintenance dosing.
What does Skyrizi treat?Skyrizi is used for psoriatic arthritis, plaque psoriasis, and Crohn's disease.
How long until I see improvement with Skyrizi?Response times vary; many patients notice improvement within the first few months of starting therapy.
Book an appointment to discuss Skyrizi therapy with Scottsdale Rheumatology Center.
Related: Psoriatic Arthritis | Infusion Suite
